MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
Conditions: Acute Graft Versus Host Disease in Intestine; Steroid Refractory GVHD Intervention: Drug: MaaT013 Sponsor: MaaT Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Pharmaceuticals | Research